CLINICAL TRIALS PROFILE FOR TECOVIRIMAT
✉ Email this page to a colleague
All Clinical Trials for Tecovirimat
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00431951 ↗ | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2007-02-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers. |
| NCT00431951 ↗ | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Completed | SIGA Technologies | Phase 1 | 2007-02-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers. |
| NCT00728689 ↗ | Phase I Trial of an Investigational Small Pox Medication | Completed | National Institutes of Health (NIH) | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers. |
| NCT00728689 ↗ | Phase I Trial of an Investigational Small Pox Medication | Completed | SIGA Technologies | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers. |
| NCT00907803 ↗ | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | Completed | National Institutes of Health (NIH) | Phase 2 | 2009-06-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials. |
| NCT00907803 ↗ | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | Completed | SIGA Technologies | Phase 2 | 2009-06-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials. |
| NCT02080767 ↗ | Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure | Available | U.S. Army Medical Research and Development Command | 1969-12-31 | The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tecovirimat
Condition Name
Clinical Trial Locations for Tecovirimat
Trials by Country
Clinical Trial Progress for Tecovirimat
Clinical Trial Phase
Clinical Trial Sponsors for Tecovirimat
Sponsor Name
